In the Phase 2 obesity trial, the most common adverse events were gastrointestinal: nausea, diarrhea, vomiting, and constipation. They were generally mild to moderate and tended to track the dose, showing up most during escalation.[1]
Reviewed for accuracy · Last reviewed July 7, 2026Because retatrutide is investigational, its longer-term safety profile in humans is not yet well characterized, and there is no approved label documenting rarer risks. The hedged reading is that the short-term trial data looks similar in character to other incretin peptides, but the evidence base is far smaller.
Many people find gastrointestinal effects ease as the body adjusts to a dose. Injecting after a lighter meal and holding a dose steady before the next step-up are commonly discussed ways to limit nausea.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.